Literature DB >> 32106351

Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?

Mar Riveiro-Barciela1,2, Ariadna Rando-Segura3, Ana Barreira-Díaz1, Marta Bes2,4, Sofía P Ruzo5, Maria Piron2,4, Josep Quer2,5, Silvia Sauleda2,4, Francisco Rodríguez-Frías2,6, Rafael Esteban1,2, María Buti1,2.   

Abstract

Hepatitis E virus (HEV) is the leading cause of acute hepatitis worldwide. The minimum criterion for diagnosis of acute infection is detection of anti-HEV antibodies, although there are scant data on IgM duration. Our aim was to assess the persistence of HEV markers after acute self-limited hepatitis E. HEV serological tests (IgM by Mikrogen and Wantai and HEV-Ag) and HEV RNA were carried out in two cohorts: (a) patients with prior acute hepatitis E (ALT >10 x ULN plus positive IgM ± HEV RNA) currently self-limited and (b) 50 blood donors with positive HEV RNA. Among 25 cases of prior acute hepatitis E, after a median follow-up of 34 months, all presented undetectable HEV RNA. However, anti-HEV IgM remained detectable in 14 (56%) by Mikrogen, 6 (24%) by Wantai and none for HEV-Ag. Anti-HEV IgM tested positive in 80%-100% within the second year and 17%-42% over 3 years later, by Wantai and Mikrogen, respectively. Among HEV RNA-positive donors, 12 (25%) tested positive for either IgM by Mikrogen or Wantai, 9 (18%) for both and 18 (36%) for HEV-Ag. HEV-Ag positivity was more likely as HEV RNA was higher (14% if <2.2 log IU/mL; 64% if RNA ≥ 3.7). Overall, HEV-Ag performed best, with a positive predictive value of 100% and diagnostic accuracy of 57%. Anti-HEV IgM exhibited unexpectedly long persistence after a self-limited acute hepatitis E. HEV-Ag had the best performance and could be especially useful in settings where HEV RNA is not available.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  HEV antigen; anti-HEV IgM Mikrogen; anti-HEV IgM Wantai; diagnosis; hepatitis E virus

Year:  2020        PMID: 32106351     DOI: 10.1111/jvh.13285

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  6 in total

1.  Dynamics of Hepatitis E Virus (HEV) Antibodies and Development of a Multifactorial Model To Improve the Diagnosis of HEV Infection in Resource-Limited Settings.

Authors:  Jie Lu; Yan Huang; Peiyun Wang; Qing Li; Ziqiang Li; Jiayuan Jiang; Qing Guo; Honglian Gui; Qing Xie
Journal:  J Clin Microbiol       Date:  2021-01-21       Impact factor: 5.948

2.  Diagnostic Performance of an Automated System for Assaying Anti-Hepatitis E Virus Immunoglobulins M and G Compared with a Conventional Microplate Assay.

Authors:  Florence Abravanel; Delphine Parraud; Sabine Chapuy-Regaud; Marcel Miedouge; Estelle Bonnin; Margaux Larrieu; Alexandre Aversenq; Sébastien Lhomme; Jacques Izopet
Journal:  Viruses       Date:  2022-05-17       Impact factor: 5.818

3.  Anti-HEV IgG Avidity Testing: Utility for Diagnosing Acute and Resolved Genotype 3 Infections.

Authors:  Claudia Minosse; Daniele Lapa; Antonio Coppola; Federica Rapagna; Gianpiero D'Offizi; Chiara Taibi; Raffaella Lionetti; Maria Rosaria Capobianchi; Fiona McPhee; Anna Rosa Garbuglia
Journal:  Viruses       Date:  2021-02-03       Impact factor: 5.048

Review 4.  Transfusion-transmitted hepatitis E: What we know so far?

Authors:  Carmen Ka Man Cheung; Sunny Hei Wong; Alvin Wing Hin Law; Man Fai Law
Journal:  World J Gastroenterol       Date:  2022-01-07       Impact factor: 5.742

5.  Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017‒2020.

Authors:  Marta Bes; Maria I Costafreda; Mar Riveiro-Barciela; Maria Piron; Angie Rico; Josep Quer; Lluis Puig; Silvia Sauleda
Journal:  Emerg Infect Dis       Date:  2022-01       Impact factor: 6.883

6.  Characterization of Chronic Hepatitis E Virus Infection in Immunocompetent Rabbits.

Authors:  Chunnan Liang; Chenyan Zhao; Tianlong Liu; Bo Liu; Zhiguo Liu; Huili Huang; Wei Liu; Minghai Zhao; Nan Xu; Qiong Lu; Jianhui Nie; Li Zhang; Weijin Huang; Ruiping She; Youchun Wang
Journal:  Viruses       Date:  2022-06-09       Impact factor: 5.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.